The BRIC diabetes drugs market is expected to grow from $3.9 billion in 2009 to reach $8.7 billion by 2014, growing at a CAGR of 17.1% from 2009 to 2014. Oral drugs accounted for around 65% of the market in 2009

Dallas, TX -- (SBWire) -- 05/04/2010 -- The report on BRIC Diabetes Drugs Market analyzes the market for oral drugs and injectables in BRIC economies over the period 2009 to 2014. The report measures and forecasts the BRIC market for diabetes drugs; and analyzes the major market drivers, restraints, and opportunities.

Browse more than 15 market data tables and in-depth TOC on BRIC Diabetes Drugs Market.

Early buyers will receive 10% customization of reports.

http://www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html

The BRIC diabetes drugs market is expected to grow from $3.9 billion in 2009 to reach $8.7 billion by 2014, growing at a CAGR of 17.1% from 2009 to 2014. Oral drugs accounted for around 65% of the market in 2009, but injectables are expected to have a higher CAGR of 21.9%.

The slowdown of the pharma market growth in developed economies has concentrated investor interest on BRIC nations, where the diabetes drug market has benefitted significantly from government initiatives for spreading patient awareness, and the subsequent increase in the uptake of novel drugs such as incretin mimetics (Eli Lilly’s Byetta) and dipeptidyl inhibitors (Merck’s Januvia and Novartis’ Galvus).

SCOPE AND FORMAT

The report analyzes the BRIC Diabetes Drugs market into the following segments:
• Injectables Market (Insulin, exenatide)
• Oral Drugs Market (Metformin, sulfonylureas, thaizolidinediones, dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors, combination medications)

In addition to market tables for each submarket, each section of the report will provide market trends, drivers, and opportunities. The report also draws a competitive landscape, profiling the key players and the top-selling products in the diabetes drug market in BRIC.

Analyst Briefing Presentation on the BRIC Diabetes Drugs Market to be held on 4th May 2010
The Healthcare practice at MarketsandMarkets is pleased to announce its Analyst Briefing Presentation on the BRIC Diabetes Drugs Market to be held on 4th May 2010. This analyst briefing focuses on the BRIC diabetes drugs market over the period 2009 to 2014. The agenda for the briefing includes a discussion on key high-growth markets, identifying the growth trends in products and services. The briefing will also cover the market’s competitive scenario and trends and opportunities in the macro- and micro-markets of Brazil, Russia, India, and China.

Table of contents

Executive summary
Market Overview
Market Analysis
Antidiabetes drugs market
Competitive Landscape

1 Introduction
1.1 Key Take Aways
1.2 Report Description
1.3 Market Estimates and Forecasts
1.4 Stakeholders
1.5 Research Methodology
2 SUMMARY
3 Market overview
3.1 Drivers
3.1.1 Rising number of diabetics in BRIC
3.1.2 Uptake of novel drugs drive sales
3.1.3 BRIC government initiatives
3.1.4 complexity of Alternative diabetes management therapies
3.2 Restraints
3.2.1 Low patient awareness
3.2.2 Cost sensitivity
3.3 Opportunities
3.3.1 Diabetes vaccines & inhalable insulin
3.3.2 Increasing diabetes care centers
3.4 competitive analysis, by region
3.5 competitive analysis, by segment
3.6 competitive analysis, by products
3.7 Age group analysis
3.8 Key findings
4 Market Analysis
4.1 Brazil diabetes drugs market
4.1.1 Drivers & Restraints
4.1.1.1 Initiatives by the Brazilian government
4.1.1.2 Patent expiry of key branded drugs
4.1.1.3 Counterfeiting of drugs
4.1.2 Brazilian government supportive of Local players
4.1.3 Distribution network in brazil
4.1.4 Reimbursement scenario
4.1.5 Regulatory environment
4.2 Russia diabetes drugs market
4.2.1 DRIVERS & restraints
4.2.1.1 Educational programs for self care
4.2.1.2 Paucity of healthcare personnel
4.2.2 Distribution network
4.2.3 Regulatory environment
4.3 India diabetes market
4.3.1 DRIVERS & Opportunities
4.3.1.1 Highest number of diabetics in the world
4.3.1.2 New Budget earmarks more funds for diabetes control
4.3.2 RESTRAINTS
4.3.2.1 Cost issues
4.3.2.2 Low level of patient awareness
4.3.3 Regulatory environment
4.4 China diabetes drugs market
4.4.1 competitive landscape
4.4.2 Diabetes prevalence in provinces
4.4.3 Distribution network
4.4.4 Drivers & restraints
4.4.4.1 Chinese government’s policy initiatives
4.4.4.2 Limited infrastructure for diabetes care
4.4.5 Reimbursement scenario
4.4.6 Regulatory environment
5 Anti-diabetes Drugs Market
5.1 Injectables
5.1.1 Insulin
5.1.2 Drivers, Restraints & Opportunities
5.1.2.1 Shift from oral antidiabetic drugs to insulin
5.1.2.2 Cost issues
5.1.2.3 Development of novel insulin delivery methods
5.1.3 Incretin mimetics
5.1.4 Exenatide versus insulin
5.2 Oral antidiabetic drugs
5.2.1 Drivers & restraints
5.2.1.1 Novel drugs drive market growth
5.2.1.2 Side effects & no long term control
5.2.1.3 Patent expiries of blockbuster drugs
5.2.2 Opportunities
5.2.3 Metformin
5.2.4 Sulfonylureas
5.2.5 Sulfonylurea v/s Metformin
5.2.6 Thiazolidinediones
5.2.7 Meglitinides
5.2.8 Alpha glucosidase inhibitors
5.2.9 Dipeptidyl peptidase inhibitors
5.2.10 Combination medications
6 Competitive Landscape
6.1 BRIC OAD market share
6.2 BRIC INSULIN MARKET SHARE
6.3 Evolution of anti-diabetic drugs
7 Company Profiles
7.1 Abbott Laboratories
7.2 Aurobindo Pharma Ltd
7.3 Bayer Healthcare AG
7.4 Biocon Ltd
7.5 Boehringer Ingelheim
7.6 Bristol-Myers Squibb
7.7 Dr. Reddy's Laboratories Ltd
7.8 Eli Lilly and Company
7.9 Glenmark Pharmaceuticals Ltd
7.1 GlaxoSmithKline plc
7.11 Lupin Ltd
7.12 Merck & Co. Inc.
7.13 novo nordisk a/s
7.14 Piramal Healthcare Ltd
7.15 Ranbaxy Laboratories Ltd
7.16 Roche Holding Ltd
7.17 Sanofi-Aventis
7.18 Shreya Life Sciences Pvt Ltd
7.19 Sun Pharma Industries Ltd
7.20 Takeda Pharmaceuticals Company
7.21 Zydus Cadila Healthcare Ltd

To register your participation, please click here.
http://www.marketsandmarkets.com/AnalystBriefing/BRIC-Diabetes-Drugs.asp

Related Reports

http://www.marketsandmarkets.com/Market-Reports/anti-counterfeit-packaging-advanced-technologies-and-global-market-129.html
http://www.marketsandmarkets.com/Market-Reports/global-weight-loss-and-gain-market-research-28.html
http://www.marketsandmarkets.com/Market-Reports/drug-and-device-combination-101.html

About MarketsandMarkets
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

M&M covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. Browse all our titles at http://www.marketsandmarkets.com

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: sales@marketsandmarkets.com
http://www.marketsandmarkets.com